Analysts Set Progyny, Inc. (NASDAQ:PGNY) Target Price at $24.90

Progyny, Inc. (NASDAQ:PGNY) has been assigned an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $24.90.

A number of equities analysts have recently issued reports on the company. Leerink Partners upgraded Progyny from a “market perform” rating to an “outperform” rating and set a $28.00 price target on the stock in a research note on Tuesday, July 8th. Raymond James Financial set a $28.00 price target on Progyny in a research note on Friday, August 8th. Canaccord Genuity Group dropped their price target on Progyny from $23.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, May 12th. Leerink Partnrs upgraded Progyny from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 price target (up from $26.00) on shares of Progyny in a research note on Friday, August 8th.

Insider Buying and Selling at Progyny

In other news, Director Cheryl Scott sold 2,675 shares of the company’s stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total value of $59,037.25. Following the completion of the sale, the director directly owned 14,112 shares in the company, valued at $311,451.84. This represents a 15.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Kevin K. Gordon sold 2,500 shares of the company’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $22.04, for a total value of $55,100.00. Following the completion of the sale, the director owned 12,501 shares of the company’s stock, valued at $275,522.04. This trade represents a 16.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System grew its stake in shares of Progyny by 0.7% during the 2nd quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after acquiring an additional 457 shares during the period. New York State Teachers Retirement System lifted its stake in shares of Progyny by 0.7% during the 1st quarter. New York State Teachers Retirement System now owns 73,200 shares of the company’s stock valued at $1,635,000 after buying an additional 500 shares in the last quarter. Leibman Financial Services Inc. lifted its stake in shares of Progyny by 1.1% during the 2nd quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company’s stock valued at $1,011,000 after buying an additional 513 shares in the last quarter. Teza Capital Management LLC lifted its stake in shares of Progyny by 5.4% during the 2nd quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after buying an additional 516 shares in the last quarter. Finally, Oxford Asset Management LLP lifted its stake in shares of Progyny by 4.3% during the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after buying an additional 531 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors.

Progyny Price Performance

PGNY stock opened at $22.74 on Friday. Progyny has a 1-year low of $13.39 and a 1-year high of $26.76. The business has a fifty day moving average price of $22.45 and a 200-day moving average price of $22.17. The stock has a market capitalization of $1.96 billion, a P/E ratio of 38.54, a P/E/G ratio of 2.01 and a beta of 1.32.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.23). The business had revenue of $332.87 million during the quarter, compared to analysts’ expectations of $315.70 million. Progyny had a return on equity of 10.69% and a net margin of 4.28%.The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.17 EPS. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. As a group, analysts anticipate that Progyny will post 0.6 earnings per share for the current year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.